Three-dimensional radiobiological dosimetry (3D-RD) with 124I PET for 131I therapy of thyroid cancer

被引：0
作者：
George Sgouros
Robert F. Hobbs
Francis B. Atkins
Douglas Van Nostrand
Paul W. Ladenson
Richard L. Wahl
机构：
[1] Johns Hopkins University,The Russell H. Morgan Department of Radiology, Division of Nuclear Medicine
[2] School of Medicine,Division of Nuclear Medicine
[3] The Washington Hospital Center,Department of Endocrinology
[4] Johns Hopkins University,undefined
[5] School of Medicine,undefined
来源：
European Journal of Nuclear Medicine and Molecular Imaging | 2011年 / 38卷
关键词：
Three-dimensional radiobiological dosimetry; Radioiodine therapy; Thyroid cancer; Positron emission tomography;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Radioiodine therapy of thyroid cancer was the first and remains among the most successful radiopharmaceutical (RPT) treatments of cancer although its clinical use is based on imprecise dosimetry. The positron emitting radioiodine, 124I, in combination with positron emission tomography (PET)/CT has made it possible to measure the spatial distribution of radioiodine in tumors and normal organs at high resolution and sensitivity. The CT component of PET/CT has made it simpler to match the activity distribution to the corresponding anatomy. These developments have facilitated patient-specific dosimetry (PSD), utilizing software packages such as three-dimensional radiobiological dosimetry (3D-RD), which can account for individual patient differences in pharmacokinetics and anatomy. We highlight specific examples of such calculations and discuss the potential impact of 124I PET/CT on thyroid cancer therapy.
引用
收藏
页码：41 / 47
页数：6
相关论文
共 174 条
[1]  
Cooper DS(2009)Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer Thyroid 19 1167-1214
[2]  
Doherty GM(2002)Dosimetrically determined doses of radioiodine for the treatment of metastatic thyroid carcinoma Thyroid 12 121-134
[3]  
Haugen BR(2005)Radioiodine therapy for thyroid cancer and hyperthyroidism in patients with end-stage renal disease on hemodialysis Thyroid 15 1321-1331
[4]  
Kloos RT(2006)A pragmatic protocol for I-131 rhTSH-stimulated ablation therapy in patients with renal failure Clin Nucl Med 31 454-457
[5]  
Lee SL(2004)Patient-specific dosimetry for 131I thyroid cancer therapy using 124I PET and 3-dimensional-internal dosimetry (3D-ID) software J Nucl Med 45 1366-1372
[6]  
Mandel SJ(2010)Pre-therapeutic (124)I PET(/CT) dosimetry confirms low average absorbed doses per administered (131)I activity to the salivary glands in radioiodine therapy of differentiated thyroid cancer Eur J Nucl Med Mol Imaging 37 884-895
[7]  
Mazzaferri EL(2006)Validation of a personalized dosimetric evaluation tool (Oedipe) for targeted radiotherapy based on the Monte Carlo MCNPX code Phys Med Biol 51 601-616
[8]  
McIver B(1997)Three-dimensional dosimetry for intralesional radionuclide therapy using mathematical modeling and multimodality imaging J Nucl Med 38 1059-1066
[9]  
Pacini F(1997)Implementation of a Monte Carlo dosimetry method for patient-specific internal emitter therapy Med Phys 24 1163-1172
[10]  
Schlumberger M(1997)Implementation and evaluation of patient-specific three-dimensional internal dosimetry J Nucl Med 38 301-308
12345678910